Advertisement

Topics

Morphotek(R), Inc. Company Profile

22:11 EDT 25th September 2017 | BioPortfolio


News Articles [10 Associated News Articles listed on BioPortfolio]

Morphotek Announces An Agreement With Fujirebio Diagnostics, Inc. To Commercialize The CA125 II Assay As A Companion Diagnostic For Farletuzumab

  Life Sciences Jobs   ...

Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th ...

MORAb-202 is a novel ADC that uses a cathepsin-cleavable linker to combine investigational farletuzumab with a microtubule inhibitor payload, eribulin *.  Farletuzumab is a Read more...

Morphotek Announces Collaboration Agreement With The Johns Hopkins University To Research And ...

Gene splicing is a normal biological process cells use to generate protein variants from a single gene. Cancer-specific mutations may affect genes that regulate this Read more...

Morphotek Announces Collaboration Agreement With The Johns Hopkins University To Research And Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens

EXTON, Pa., Sept. 6, 2017 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Johns Hopkins University School of Medicine&nb...

Morphotek Announces Top-Line Results of a Phase III Study of Farletuzumab in Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer

EXTON, Pa., Jan. 10, 2013 /PRNewswire/ -- Morphotek® Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farle...

Morphotek Achieves LEED® Certification For New Pilot Plant

EXTON, Pa., July 3, 2013 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has achieved LEED® certification for its new 60,000-square-foot pilot plant fac...

Morphotek®, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®

EXTON, Pa., Sept. 5, 2017 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaboration and license agreement with Fujirebio Diagno...

Morphotek Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23082017] Prices from USD $250

SummaryMorphotek Inc Morphotek, a subsidiary of Eisai Co Ltd is a clinicalstage biotech company that develops novel classes of biological based products. The company offers a pipeline of monoclonal an...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Morphotek Inc.

Morphotek is a biopharmaceutical company developing therapeutic monoclonal antibodies through the use of a proprietary human antibody technology. The company employs its technology to discover and dev...

Morphotek, Inc.

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and pro...

Morphotek(R), Inc.

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

More Information about "Morphotek(R), Inc." on BioPortfolio

We have published hundreds of Morphotek(R), Inc. news stories on BioPortfolio along with dozens of Morphotek(R), Inc. Clinical Trials and PubMed Articles about Morphotek(R), Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Morphotek(R), Inc. Companies in our database. You can also find out about relevant Morphotek(R), Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record